Cartesian Therapeutics (RNAC) Depreciation & Amortization (CF) (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Depreciation & Amortization (CF) data on file, last reported at $615000.0 in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 46.8% year-over-year to $615000.0 in Q1 2026; TTM through Mar 2026 was $2.4 million, a 13.84% increase from a year earlier, with the FY2025 full-year figure at $3.0 million, up 157.08% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $615000.0, up from $608000.0 in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for RNAC reached as high as $1.2 million in Q1 2025 and fell as low as $176000.0 in Q2 2023.
• Historically, Depreciation & Amortization (CF) has averaged $403235.3 across 5 years, with a median of $345000.0 in 2022.
• Across the five-year window, Depreciation & Amortization (CF) sank 48.99% in 2023 and surged 531.69% in 2025, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $241000.0 in 2022, then advanced by 12.86% to $272000.0 in 2023, then jumped by 78.68% to $486000.0 in 2024, then increased by 25.1% to $608000.0 in 2025, then climbed by 1.15% to $615000.0 in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $615000.0 in Q1 2026, $608000.0 in Q4 2025, and $606000.0 in Q3 2025.